Janssen HL - Search Results

1

Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.

de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW; Liver and Thrombosis Study Group. de Bruijne EL, et al. Among authors: janssen hl. Thromb Haemost. 2007 Feb;97(2):181-5. Thromb Haemost. 2007. PMID: 17264944

2

Graves' hyperthyroidism in a patient with primary sclerosing cholangitis. Coincidence or combined pathogenesis?

Janssen HL, Smelt AH, van Hoek B. Janssen HL, et al. Eur J Gastroenterol Hepatol. 1998 Mar;10(3):269-71. doi: 10.1097/00042737-199803000-00015. Eur J Gastroenterol Hepatol. 1998. PMID: 9585034

3

[Portal vein thrombosis: causes and treatment].

Janssen HL, van Buuren HR, Leebeek FW, Schalm SW. Janssen HL, et al. Ned Tijdschr Geneeskd. 1999 Oct 9;143(41):2037-41. Ned Tijdschr Geneeskd. 1999. PMID: 10560543 Review. Dutch.

4

Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.

Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Janssen HL, et al. Blood. 2000 Oct 1;96(7):2364-8. Blood. 2000. PMID: 11001884 Free article.

5

Changing perspectives in portal vein thrombosis.

Janssen HL. Janssen HL. Scand J Gastroenterol Suppl. 2000;(232):69-73. Scand J Gastroenterol Suppl. 2000. PMID: 11232496 Review.

6

Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.

Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, De Groot PG. Lisman T, et al. Among authors: janssen hl. Gastroenterology. 2001 Jul;121(1):131-9. doi: 10.1053/gast.2001.25481. Gastroenterology. 2001. PMID: 11438502

7

The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome.

Tang TJ, Batts KP, de Groen PC, van Hoek B, Haagsma EB, Hop WC, Janssen HL. Tang TJ, et al. Among authors: janssen hl. J Hepatol. 2001 Sep;35(3):338-43. doi: 10.1016/s0168-8278(01)00131-3. J Hepatol. 2001. PMID: 11592594

8

Extrahepatic portal vein thrombosis: aetiology and determinants of survival.

Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, Chamuleau RA, van Hattum J, Vleggaar FP, Hansen BE, Rosendaal FR, van Hoek B. Janssen HL, et al. Gut. 2001 Nov;49(5):720-4. doi: 10.1136/gut.49.5.720. Gut. 2001. PMID: 11600478 Free PMC article.

9

Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome.

Darwish Murad S, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, van Hoek B, Hansen BE, Rosendaal FR, Janssen HL. Darwish Murad S, et al. Among authors: janssen hl. Hepatology. 2004 Feb;39(2):500-8. doi: 10.1002/hep.20064. Hepatology. 2004. PMID: 14768004 Free article.

10

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL. van Zonneveld M, et al. Among authors: janssen hl. Hepatology. 2004 Mar;39(3):804-10. doi: 10.1002/hep.20128. Hepatology. 2004. PMID: 14999700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

635 results

Search Page

Filters